Purpose Within the last 30 years, no consistent survival benefits have been recorded for anticancer agents of advanced hepatocellular carcinoma (HCC), except for the multikinase inhibitor sorafenib (Nexavar?), which clinically achieves only ~3 weeks overall survival benefit. drug-loaded CNTs (CNTs-SFN). The restorative effectiveness of the new method was estimated and compared to that of standard… Continue reading Purpose Within the last 30 years, no consistent survival benefits have